Answers are grounded in this paper and cite their sources.
.. ..•. . . . . . . .. .. . . .. ........ .. .. . . . . . . . . . . .. .. .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ....... . . . . . . . .... . . .. . . . . . . . . . . • . . . . . . . . . • • . . . . . . . . • . . . . . . . . . . . . . . • . • . . . • • .•... ......... , . . . 93 Rifampinl is a recently developed, oral ly active, semisynthetic derivative of rifamycin B and it has great promise as an effective and major antituber culosis drug. It is also active against many Gram-positive cocci. In addition, the drug has other actions which have both practical and theoretical implica tions.
No takes yet. Share an insight, caveat, or question.
William Lester (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: